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lphaviruses and ﬂaviviruses infect cells through
low pH-dependent membrane fusion reactions
mediated by their structurally similar viral fusion
proteins. During fusion, these class II viral fusion proteins
trimerize and refold to form hairpin-like structures, with the
domain III and stem regions folded back toward the target
membrane-inserted fusion peptides. We demonstrate that
exogenous domain III can function as a dominant-negative
inhibitor of alphavirus and ﬂavivirus membrane fusion and
A
 
infection. Domain III binds stably to the fusion protein, thus
preventing the foldback reaction and blocking the lipid
mixing step of fusion. Our data reveal the existence of a
relatively long-lived core trimer intermediate with which
domain III interacts to initiate membrane fusion. These
novel inhibitors of the class II fusion proteins show cross-
inhibition within the virus genus and suggest that the do-
main III–core trimer interaction can serve as a new target
for the development of antiviral reagents.
 
Introduction
 
The alphaviruses and flaviviruses, which are members of the
Togaviridae and Flaviviridae families, include several serious
human and animal pathogens that are disseminated in nature by
mosquito or tick vectors (for reviews see Lindenbach and Rice,
2001; Schlesinger and Schlesinger, 2001). The alphaviruses
eastern equine encephalitis virus, western equine encephalitis
virus, and Venezuelan equine encephalitis virus cause periodic
epidemics of severe encephalitis in humans (Weaver and Bar-
rett, 2004). Important flavivirus pathogens include Japanese
encephalitis virus, tick-borne encephalitis virus (TBE), yellow
fever virus, West Nile virus, and dengue virus (DV). Current es-
timates are that more than one third of the world’s population
lives in dengue fever endemic areas, with 
 
 
 
100 million cases of
dengue infection and 500,000 cases of the more lethal complica-
tion, dengue hemorrhagic fever, per year (Clarke, 2002; Gubler,
2002). Given the known spread of mosquito vectors into new re-
gions, several alphaviruses and flaviviruses are also potential
emerging pathogens (for review see Mackenzie et al., 2004;
Weaver and Barrett, 2004). There are no effective therapeutic
drugs for these viruses, and vaccine development, although an
important focus of research, is complicated by the potential for
antibody enhancement of infection, as observed in the case of
DV (Halstead, 1988; for review see Mackenzie et al., 2004).
Alphaviruses and flaviviruses are small, spherical viruses
containing plus-strand RNA genomes packaged with a capsid
protein. The nucleocapsid is enveloped by a lipid bilayer con-
taining the virus membrane fusion protein (alphavirus E1 or
flavivirus E). This transmembrane (TM) protein mediates the
fusion of the virus membrane with the cell membrane, delivering
the viral RNA into the cytoplasm and initiating virus infection.
In mature virions, alphavirus E1 is associated as a heterodimer
with the viral E2 protein, whereas the flavivirus E protein is
found as an E–E homodimer. Infection by alphaviruses and fla-
viviruses occurs via an initial interaction of the virus with cell
surface receptors, followed by internalization of the virus by
endocytosis (for reviews see Kielian et al., 2000; Heinz and Al-
lison, 2001). Virus membrane fusion is triggered by the mildly
acidic pH within the endocytic pathway and is specifically
blocked by inhibitors of endosome acidification. Low pH
causes a dramatic rearrangement of the fusion protein, dissoci-
ating its dimeric interactions and producing a target membrane-
inserted homotrimer (HT) that is believed to drive the membrane
fusion reaction (Wahlberg and Garoff, 1992; Allison et al.,
1995; Kielian et al., 1996).
Although the alphavirus and flavivirus fusion proteins do
not have detectable amino acid sequence similarity, they have
remarkably similar secondary and tertiary structures, indicating
their evolutionary relationship and leading to their classification
as the inaugural members of the class II virus fusion proteins
(Lescar et al., 2001). The neutral pH structures of the fusion
protein ectodomains have been determined for the alphavirus
Semliki Forest virus (SFV; Lescar et al., 2001) and the flavi-
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viruses TBE, DV2, and DV3 (Rey et al., 1995; Modis et al.,
2003, 2005; Zhang et al., 2004). The proteins are elongated
molecules composed almost entirely of 
 
  
 
strands and contain
three domains: the centrally located domain I; domain II, which
is located at one side of domain I and contains the target-
membrane–interacting fusion peptide loop at its tip; and an Ig-
like domain III, which is connected to the other side of domain I
(Fig. 1 A). Although not present in the ectodomain structure, in
the full-length proteins the stem region and TM anchor are
found at the COOH terminus of domain III, at the opposite end
of the protein from the fusion loop. The fusion proteins are ar-
ranged with icosahedral symmetry and lie tangential (almost
parallel) to the virus membrane (Lescar et al., 2001; Kuhn et
al., 2002; W. Zhang et al., 2002).
Treatment of the SFV fusion protein ectodomain, E1*, at
low pH in the presence of target membranes converts the pro-
tein to a membrane-inserted HT (Klimjack et al., 1994; Gib-
bons et al., 2004a). The three-dimensional structure of the
E1*HT reveals that during trimerization, domain III and the
stem region of E1 move 
 
 
 
37 Å toward the fusion loop (Fig. 1 A;
Gibbons et al., 2004b). This foldback reaction generates a hair-
pin-like conformation with the fusion loop and the TM domain
at the same end of the E1 trimer. The structures of the DV and
TBE HTs are remarkably similar to that of SFV, although the
stem region of the protein is not present in these ectodomains
(Bressanelli et al., 2004; Modis et al., 2004). Thus, the alphavi-
rus and flavivirus membrane fusion proteins share common
structural and functional features in both their prefusion and
postfusion conformations.
Although the class I viral membrane fusion proteins are
structurally very different from the class II proteins, the class I
proteins are known to refold to a hairpin-like structure during
fusion (for reviews see Skehel and Wiley, 2000; Jardetzky and
Lamb, 2004; Earp et al., 2005). Class I proteins are exemplified
by the influenza virus HA and the HIV-1 gp41. The class I pro-
teins are trimeric both before and after fusion. In the postfusion
conformation, the membrane-proximal COOH-terminal re-
gions interact with a more NH
 
2
 
-terminal trimeric 
 
 
 
-helical
coiled–coil domain to form a “trimer of hairpins” that brings
the fusion peptides and TM domains together. Importantly, for
several class I proteins, peptides containing sequences of these
NH
 
2
 
- or COOH-terminal interacting regions can bind to the vi-
ral fusion protein and inhibit fusion and infection by preventing
refolding to the final hairpin conformation (for review see
Moore and Doms, 2003). This dominant-negative approach is
exemplified by the HIV peptide T20/Enfuvirtide, a licensed an-
tiretroviral drug that corresponds to the COOH-terminal helix
of gp41 (Wild et al., 1993).
Inhibitors of the class II fusion proteins would be very
valuable tools in studying fusion mechanisms and developing
antiviral agents for these important viruses. The structures of
the class II fusion proteins suggest several features that might
serve as targets for inhibitors of the fusion reaction. The pH 7.0
form of the DV E protein reveals a hydrophobic pocket within
a flexible “hinge” region between domains I and II (Modis et
al., 2003). Because the hinge changes its angle during the tran-
sition to the trimer form, molecules that bind to the hydrophobic
pocket may inhibit hinge flexibility and block fusion (Modis et
al., 2003). The structure of the SFV E1*HT reveals that the
stem region of the protein interacts along the “core trimer,”
which is the central region of the trimer containing domains I
and II (Gibbons et al., 2004b). Thus, the stem peptide and its
HT interaction site are potential targets (Bressanelli et al.,
2004; Modis et al., 2004). One of the most prominent features of
the class II protein refolding reaction is the striking movement of
Figure 1. Summary of domain III proteins. (A) Structure of the SFV E1
ectodomain in the neutral pH monomer conformation (left; modified from
Gibbons et al., 2004b) and in the low pH-induced trimer conformation
(right), showing a single E1 protein of the trimer (drawn using PyMOL; De-
Lano, 2002). The colors indicate domains I (red), II (yellow), and III (blue),
and the fusion loop (fl; orange) at the tip of domain II. The movement of do-
main III and the stem toward the fusion loop is indicated by the small black
arrow. (B) Linear diagram of sequences of SFV E1 and DV2 E and domain
III constructs, showing the boundaries of the domains, stem region, and TM
anchor region. The SFV E1 domain III proteins are as follows: DIII (residues
291–383), DIIIS (291–412), His-DIII (His tag plus 291–383), and His-DIIIS
(His tag plus 291–412). The DV2 E domain III proteins are as follows:
DV2DIIIH1 (296–415) and His-DV2DIII (His tag plus 296–395). The His
tag adds 36 residues at the NH2 terminus; untagged proteins contain an
added methionine at the NH2 terminus. (C) 2  g of each purified domain III
protein was treated with or without 10 mM DTT, alkylated, and analyzed
by SDS-PAGE. Marker proteins are shown on the left with their molecular
masses listed in kilodaltons. (D) The molecular mass of each domain III pro-
tein was measured by mass spectrometry and compared with the mass cal-
culated from the amino acid sequence. The predicted error rate is 0.01%.
The mass for DV2DIIIH1was calculated without the added NH2-terminal me-
thionine because the measured mass indicated that this residue was not
contained in the protein. (E) Elution profiles of 50  M His-DIIIS and DIIIS on
Superdex G-75 in 0.1 M Na Acetate, pH 5.5. 
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domain III and the stem toward the trimer tip (Fig. 1 A). Al-
though domain III undergoes a dramatic reorientation during
fusion, the significance of domain III in the fusion protein re-
folding reaction and in driving membrane fusion is unknown.
We demonstrate here that recombinant forms of domain
III can inhibit the low pH-dependent fusion reactions of the al-
phaviruses and flaviviruses. Domain III proteins show cross-
inhibition within each virus genus, suggesting the presence of
critical interaction sites. Studies of SFV demonstrate that inhi-
bition occurs by a dominant-negative mechanism in which ex-
ogenous domain III binds stably to an E1 trimer intermediate
and blocks the initial mixing of the target and virus lipid bilay-
ers. Our results suggest a new antiviral strategy that should be
generally applicable to all class II viruses.
 
Results
 
Generation and characterization of 
domain III proteins
 
Several previous studies have demonstrated that flavivirus do-
main III can be produced in bacteria as fusion proteins (Bhard-
waj et al., 2001; Volk et al., 2004), as epitope-tagged proteins
(Wu et al., 2003; Hung et al., 2004), or by refolding of the mol-
ecule from inclusion bodies (Jaiswal et al., 2004). The structures
of recombinant domain III from West Nile virus (Volk et al.,
2004) and Japanese encephalitis virus (Wu et al., 2003) were
determined by nuclear magnetic resonance and shown to be es-
sentially identical to the structure of domain III in TBE E protein
purified from virus (Rey et al., 1995). Domain III is contiguous
in the linear sequence of SFV E1 or DV E protein and forms an
Ig-like 
 
 
 
-barrel structure that has three disulfide bonds in SFV
E1 or one disulfide bond in DVE. We prepared four domain III
constructs for SFV, containing domain III with or without the
stem region and with or without an NH
 
2
 
-terminal His tag (DIII,
DIIIS, His-DIII, and His-DIIIS; Fig. 1 B). We also prepared
two constructs of domain III from the DV2 serotype, contain-
ing DV2 domain III plus the helix 1 region of the stem
(DV2DIIIH1) or DV2 domain III with an NH
 
2
 
-terminal His tag
(His-DV2DIII). The proteins were expressed in 
 
Escherichia
coli
 
, refolded using a fast dilution method successfully used to
refold proteins containing Ig-like domains (X. Zhang et al.,
2002), and purified by gel filtration chromatography. Tests of
the purified SFV proteins demonstrated that all four eluted as a
single peak at the predicted monomer position when chromato-
graphed at pH 5.5 or 8.0 (Fig. 1 E and not depicted) and mi-
grated as a single band on native gels (unpublished data). Thus,
no evidence of aggregation was observed. All of the purified
proteins migrated as a single band of the predicted size in SDS-
PAGE and showed a mobility shift upon reduction, indicating
the presence of disulfide bonds (Fig. 1 C). Analysis by mass
spectrometry confirmed the predicted protein sizes and sug-
gested that the SFV domain III proteins contain three disulfide
bonds because their measured masses are approximately six
units less than those predicted if all six cysteines are reduced
(Fig. 1 D). Similarly, the dengue domain III constructs appear to
contain the single predicted disulfide bond. The disperse loca-
tion of the cysteines in SFV domain III suggests that they can-
not form aberrant disulfides without radically changing the pro-
tein fold (Lescar et al., 2001). Thus, the presence of all three
disulfide bonds, the proteins’ high solubility (
 
 
 
10 mg/ml), and
the biological activity described in this paper strongly suggest
that all of the domain III proteins are correctly folded.
 
Inhibition of class II virus fusion and 
infection by domain III proteins
 
We screened the SFV DIII proteins for activity in a fusion-
infection assay (FIA) that quantitates low pH-dependent SFV
fusion with the plasma membrane (Vashishtha et al., 1998).
Viruses were bound to cells on ice and treated for 1 min at 37
 
 
 
C
at low pH to trigger the fusion of the virus with the plasma
membrane of the cell. This fusion results in virus infection. The
cells were cultured overnight in the presence of 20 mM NH
 
4
 
Cl
to prevent secondary infection, and the cells infected due to the
low pH pulse were quantitated by immunofluorescence. Under
these conditions, we could test the effects of domain III proteins
specifically during the binding step, the fusion step, and the
postfusion culture step. As shown in Fig. 2 A, 4 
 
 
 
M His-DIII
almost completely inhibited SFV infection of BHK cells, but
only when present during the low pH-induced fusion step. Sim-
ilar results were obtained for His-DIIIS (unpublished data). In
contrast, preincubation of the virus with domain III proteins at
37
 
 
 
C at neutral pH had no effect (unpublished data). In agree-
Figure 2. SFV E1 domain III proteins inhibit SFV fusion with target cell
membranes. (A) Exogenous domain III specifically inhibits SFV fusion. SFV
was added to BHK cells (multiplicity of infection  0.002) for 90 min on
ice (Binding). The cells were incubated at pH 7.4 (N) or pH 5.5 for 1 min
at 37 C to induce fusion (Fusion) and cultured at 28 C overnight in me-
dium containing 20 mM NH4Cl (Culture). The presence or absence of 4  M
His-DIII in each step is indicated by   or  . Infected cells were quantitated
by immunofluorescence. Results are shown as a percentage of control in-
fection in the absence of His-DIII at any step. Representative example of
two experiments. (B) The concentration dependence of inhibition by do-
main III proteins was determined using the assay in A and adding the indi-
cated concentrations of domain III proteins only during the 1-min low pH
treatment. Representative example of two experiments. 
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ment with studies showing that alphavirus receptor interaction
is mediated by the E2 protein (for review see Schlesinger and
Schlesinger, 2001), exogenous domain III proteins did not in-
hibit virus cell binding or release prebound virus from cells
(Fig. 2 A and see Fig. 6). Inhibition by domain III protein was
comparable when virus was prebound to cells at pH 6.5, 6.8,
7.4, or 8.0, or when the low pH pulse was at pH 5.5 or 6.0 (un-
published data). Comparison of the four SFV domain III pro-
teins showed that the strongest inhibition was obtained with
His-DIIIS (IC
 
50
 
 
 
 
 
0.1 
 
 
 
M), followed by His-DIII (IC
 
50
 
 
 
 
 
0.5
 
 
 
M), DIIIS (IC
 
50
 
 
 
 
 
6 
 
 
 
M), and DIII, which gave 
 
 
 
40% inhibi-
tion at a concentration of 80 
 
 
 
M (Fig. 2 B). Thus, the presence
of both the stem region and the NH
 
2
 
-terminal His tag resulted in
increased effectiveness. Although enhancement by the stem re-
gion is suggested from the structure of the low pH-induced HT,
the reason for the increase in inhibition observed with His-
tagged forms of SFV domain III is not known. The tag at the
domain III NH
 
2
 
 terminus could act by stabilizing binding to E1,
mimicking the important domain I–domain III linker region
and/or enhancing its trimeric interactions, concentrating the
protein at the membrane at low pH, preventing displacement of
the exogenous DIII by the endogenous DIII, and/or preventing
cooperative HT–HT interactions. High concentrations of His-
tagged DV2 domain III protein did not affect SFV fusion (Fig.
3 B), indicating that there is no nonspecific effect of the His tag.
The specificity of domain III inhibition was addressed by
comparing the effect of the SFV proteins on fusion of the al-
phavirus Sindbis virus (SIN) and the flavivirus DV2. The over-
all sequence of domain III is 
 
 
 
50% identical between SFV and
SIN, and the surface of domain III that interacts with the core
trimer contains several conserved residues (Gibbons et al.,
2004b). In contrast, the DV2 E protein shows no detectable se-
quence conservation with the alphavirus fusion proteins. SFV,
SIN, and DV2 all showed efficient fusion upon treatment at pH
5.5 and little fusion at pH 7.4 (Fig. 3 A). Inclusion of SFV His-
DIII or His-DIIIS during the low pH pulse inhibited SIN fusion
with comparable (or even slightly higher) efficiency to SFV fu-
sion. The SFV domain III proteins did not cause any inhibition
of DV2 fusion.
To address the general applicability of domain III inhibi-
tion to class II fusion, we tested the ability of His-DV2DIII and
DV2DIIIH1 to inhibit fusion by the DV2 and DV1 serotypes.
These two serotypes show 
 
 
 
60% overall sequence identity in
domain III. Unlike alphaviruses, flavivirus receptor binding is
directly mediated by the membrane fusion protein (Lindenbach
and Rice, 2001). Prior studies of flavivirus domain III showed
that it could block virus-cell binding (Bhardwaj et al., 2001;
Hung et al., 2004). Therefore, we prebound DV1 and DV2 to
cells in the cold and added domain III protein only during the
1-min pH pulse used to trigger fusion. As shown in Fig. 3 B,
DV2DIIIH1 strongly inhibited both DV1 and DV2 fusion
(
 
 
 
70% inhibition of DV2 at a concentration of 50 
 
 
 
M), but
showed no activity against SFV. Interestingly, His-DV2DIII
did not inhibit DV fusion, suggesting a possible role for helix 1,
an NH
 
2
 
-terminal region of the stem previously shown to pro-
mote E protein trimerization (Allison et al., 1999). We have
less information on the domain III requirements for optimal
DV inhibition and have not yet evaluated if constructs contain-
ing both helix 1 and the NH
 
2
 
-terminal His tag would show in-
creased activity. Treatment at 37
 
 
 
C for 1-min at neutral or low
pH with DV2DIIIH1 did not release prebound virus from the
cell membrane (Fig. 3 C), indicating that domain III inhibition
was not due to effects on virus receptor interaction. Exogenous
domain III can thus act as a specific inhibitor of the class
II membrane fusion reaction. The observed cross-inhibition
within the alphaviruses and flaviviruses suggests conservation
of domain III contacts.
Figure 3. Domain III proteins specifically inhibit alphavirus and flavivirus
fusion. (A) Inhibition by alphavirus domain III proteins. Viruses were
bound to BHK cells for 90 min on ice and incubated at 37 C for 1 min
under the indicated conditions. The cells were washed and cultured in
medium containing NH4Cl, and infected cells were quantitated by immuno-
fluorescence. Results are shown as a percentage of control infection (pH
5.5, no protein). (B) Inhibition by flavivirus domain III proteins. Viruses
were bound to BHK cells for 90 min on ice and incubated at 37 C for 1 min
under the indicated conditions. Infected cells were quantitated as in A.
(C) Domain III protein does not release DV2 from cells. DV2 was bound to
BHK cells for 90 min on ice and incubated at 37 C for 1 min at the indi-
cated pH in the presence or absence of 50  M DV2DIIIH1. For samples
treated at pH 7.4, cells were incubated for 2 h at 37 C and infected cells
were quantitated by immunofluorescence as in A. For samples treated at
pH 5.7, cell-associated radiolabeled virus capsid protein was quantitated
by SDS-PAGE of cell lysates. Average of three experiments. Error bars are
the mean   SD. n   3. 
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Because alphavirus receptor binding is not mediated by the
E1 protein, we used this system to test the ability of domain III
proteins to inhibit virus fusion from within the endosome, which
is the physiological route of virus infection. We infected BHK
cells with either SFV, SIN, vesicular stomatitis virus (VSV), or
DV2, in the presence or absence of 20 
 
 
 
M His-DIIIS or 40 
 
 
 
M
DIIIS. VSV, an unrelated rhabdovirus, and DV2 are important
controls because these viruses also infect cells by endocytosis
and low pH-triggered fusion (Matlin et al., 1982; Heinz and Al-
lison, 2001). After a 1-h endocytic uptake period, NH
 
4
 
Cl was
added to prevent further infection, and the primary infected cells
were quantitated by immunofluorescence. Infection by both al-
phaviruses was significantly inhibited by the inclusion of either
His-DIIIS or DIIIS (Fig. 4). In contrast, VSV and DV2 infection
was not inhibited. Compared with the FIA, inhibition of alphavi-
rus endocytic infection required a higher concentration of His-
DIIIS and also showed lower efficacy versus untagged DIIIS.
This could reflect relatively inefficient endocytic uptake of His-
DIIIS by the cells or differential routing of virus and domain III
within the endocytic pathway. Although its targeting to the
endosomal site of virus fusion is probably not optimized, it is
already clear that domain III protein can block fusion and in-
fection under physiological virus entry conditions.
 
Exogenous domain III blocks the initial 
mixing of the virus and cell membranes
 
Class II virus fusion initiates through the interaction of the fu-
sion loop with the target membrane and progresses through an
initial lipid mixing stage termed hemifusion in which the outer
leaflets of the virus and target membranes mix (Zaitseva et al.,
2005). This stage is followed by the opening of a fusion pore,
which widens to give complete fusion and content mixing, the
end stage of fusion monitored by the FIA. To test for the effects
of domain III proteins on initial lipid mixing and hemifusion,
we followed the loss of the pyrene excimer peak upon fusion of
pyrene-labeled SFV with unlabeled target cells (Chatterjee et
al., 2002). Pyrene-labeled SFV was bound to cells in the cold
and pulsed at low pH in the presence or absence of exogenous
domain III. We determined the fluorescence emission spectrum
of each virus cell mixture and compared the excimer to mono-
mer peak ratio (Ex/M). Untreated virus (unpublished data) or
virus treated at pH 7.4 showed a strong excimer peak, with an
Ex/M of 
 
 
 
0.28 (Fig. 5 A, curve a). Virus treated at pH 5.5
showed efficient fusion with the cell plasma membrane, as re-
flected in the decrease of the excimer peak and an Ex/M of
 
 
 
0.10 (Fig. 5 A, curve b). The presence of His-DIIIS caused a
concentration-dependent inhibition of the lipid mixing step
(Fig. 5 A, curves c–e). No effect was observed when His-DIIIS
was added to the sample after low pH treatment (unpublished
data). As observed in the FIA, His-DIIIS showed the highest
activity, with 
 
 
 
90% inhibition of fusion at 8 
 
 
 
M (Fig. 5 B).
Both His-DIII and DIIIS produced significant inhibition at 20
 
 
 
M, whereas the DV domain III protein gave no inhibition at
20 
 
 
 
M. A higher concentration of His-DIIIS was required to
completely inhibit pyrene virus fusion compared with the FIA,
which could reflect an intrinsic difference in the inhibitor sen-
sitivity of lipid mixing versus content mixing or the higher con-
centration of virus used in the pyrene versus FIA experiments.
 
Exogenous domain III binds to viral E1 
during fusion
 
If domain III protein is inhibiting virus fusion by preventing
the foldback of the full-length viral E1, it may interact stably
Figure 4. SFV E1 domain III proteins inhibit alphavirus infection in the
endocytic pathway. SFV, SIN, VSV, and DV2 were diluted in medium of
pH 7.2, containing the indicated concentrations of SFV domain III proteins
and incubated with BHK cells for 1 h at 20 C to allow endocytic uptake.
Infection was blocked by addition of medium containing NH4Cl, and in-
fected cells were quantitated by immunofluorescence. Data are shown as
a percentage of control infection in the absence of domain III proteins.
Error bars are the mean   SD. n   3.
Figure 5. SFV E1 domain III proteins inhibit the lipid mixing step of fusion.
(A) Fluorescence scan of pyrene-labeled SFV fused with BHK cells. Pyrene-
labeled SFV was prebound to BHK cells and incubated at 37 C for 1 min
in pH 7.4 medium without domain III protein (curve a), in pH 5.5 medium
without domain III protein (curve b), or in pH 5.5 medium with 1 (curve c),
5 (curve d), or 8  M (curve e) His-DIIIS. Background fluorescence from
cells alone was subtracted and the fluorescence emission was normalized
for each sample by setting the monomer peak at 397 nm to 5 (arbitrary
units). Representative example of three experiments. (B) Comparison of in-
hibition of lipid mixing by domain III proteins. The fusion between pyrene-
labeled SFV and BHK cells was assayed as in A, in the presence of the in-
dicated concentrations of domain III proteins. The difference between the
Ex/M at pH 7.4 and after treatment at pH 5.5 without domain III proteins
was defined as 100% (control). The difference between the ratios of the
pH 7.4 sample and each experimental sample was determined and ex-
pressed as a percentage of this control difference. Error bars are the
mean   SD. n   3. 
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with the E1 protein during inhibition. To assay for such interac-
tion, we used radiolabeled SFV and His-DIII or His-DIIIS in
the FIA. After the low pH-treatment step, the cells were lysed
in the nonionic detergent octylglucoside, which we have shown
fully solubilizes membrane-inserted E1 and disrupts intertrimer
interactions, but maintains trimer structure (Gibbons et al.,
2004a). Aliquots of the samples were immunoprecipitated us-
ing a polyclonal antibody to quantitate total E1; mAb E1a-1,
which specifically recognizes the low pH-induced conforma-
tion of E1 (Ahn et al., 1999); mAb HIS-1, which recognizes the
His tag on domain III; and two control antibodies; and were an-
alyzed by SDS-PAGE (Fig. 6 A). Equivalent amounts of radio-
labeled virus proteins were present in cells treated at neutral or
low pH with or without domain III proteins, confirming that
bound virus was not released from the cell. Upon acid treat-
ment the E1 protein was efficiently recognized by mAb E1a-1.
Inclusion of either His-DIII or His-DIIIS during low pH treat-
ment resulted in coimmunoprecipitation of the E1 protein by
the HIS-1 antibody. Quantitative analysis showed that the
amount of E1 retrieved by HIS-1 increased when increasing
amounts of domain III proteins were present during the low pH
step (Fig. 6 B). His-DIII retrieved 
 
 
 
18% of the total E1 at a
concentration of 20 
 
 
 
M. Retrieval by His-DIIIS was maximal
at 2 
 
 
 
M and 
 
 
 
50% of the total E1, similar to the amount of E1
that converted to reactivity with mAb E1a-1. His-DIIIS was
thus more efficient for both coimmunoprecipitation and fusion
inhibition. Similar to their effects on fusion activity, domain III
proteins only interacted with viral E1 when present during the
low pH treatment step and not at neutral pH (Fig. 6, A and B).
The target for exogenous domain III binding during fu-
sion could be either the E1 monomer before trimerization or a
trimeric form of E1. A general property of trimeric E1 is its rel-
ative resistance to trypsin digestion (Chatterjee et al., 2002).
We treated cell-bound radiolabeled SFV at pH 7.4 or 5.5 in the
presence of 10 
 
 
 
M His-DIII and quantitated the trypsin resis-
tance of the E1 retrieved by the indicated antibodies (Fig. 6 C).
The pH 7.4 treated monomeric E1 was almost completely di-
gested by trypsin (7% resistant). After the low pH pulse, 
 
 
 
50%
of the total E1 was in a trypsin-resistant trimer conformation,
which is in keeping with the usual efficiency of HT formation
(Gibbons and Kielian, 2002). The E1 population retrieved by
either mAb E1a-1 or the antibody to the His tag was strongly
enriched in trypsin-resistant E1. In addition, experiments with
the monomeric E1* ectodomain revealed that exogenous SFV
domain III did not bind E1* at either neutral or low pH,
whereas binding was observed when E1* was triggered to tri-
merize (Klimjack et al., 1994) by treatment with low pH and
target membranes (unpublished data). Together, these data
suggest that the trimerization of E1 produces a binding site that
interacts with exogenous domain III.
Dominant-negative binding of exogenous domain III
would be predicted to alter the conformation of the E1 HT by
preventing the folding back of the viral domain III, and conse-
quently could decrease trimer stability. Exposure of the acid-
conformation–specific mAb E1a-1 epitope on domain I closely
correlates with HT formation, although the epitope is not
formed by trimerization per se (Ahn et al., 1999). Interestingly,
concentrations of His-DIIIS above 2 
 
 
 
M led to a gradual de-
crease in the retrieval of E1 by both the anti-His antibody and
mAb E1a-1 (Fig. 6 B). This suggests that the binding of exoge-
nous domain III is directly affecting the conformation of the
E1HT. Destabilization of the trimer structure by domain III
could also explain why somewhat less trypsin-resistant trimer
was recovered after retrieval with domain III, as compared with
the acid-specific mAb (Fig. 6 C). We directly evaluated HT
stability by following the resistance of the SFV HT to dissocia-
Figure 6. SFV domain III proteins bind to tri-
meric E1 during the fusion reaction. (A) Domain
III proteins bind to E1 during fusion. 
35S-labeled
SFV was bound to BHK cells on ice and
treated at pH 7.4 or 5.5 at 37 C for 1 min in
the presence of the indicated domain III pro-
teins. Cells were washed, lysed, and immuno-
precipitated with a rabbit polyclonal antibody
against the SFV E1 and E2 protein (Rab), a
mAb against the low pH conformation of E1
(E1a-1), a mAb against the His tag (HIS-1), a
rabbit preimmune serum (Pre), or an isotype-
matched irrelevant mAb (12G5). Samples
were analyzed by SDS-PAGE and fluorogra-
phy. (B) Quantitation of samples prepared as
in A using the indicated concentrations of His-
DIII or His-DIIIS. N indicates 1 min treatment at
pH 7.4 with 2  M His-DIIIS. The total E1 in
each sample was defined as the amount of E1
immunoprecipitated by Rab. Representative
example of two experiments. (C) Domain III se-
lectively interacts with a trimeric form of E1.
Fusion reactions were triggered at pH 7.4 or
5.5 in the presence of 10  M His-DIII as in A. Samples were immunoprecipitated with the indicated antibodies, digested with trypsin where indicated,
and analyzed by SDS-PAGE. The amount of trypsin-resistant E1 was quantitated and expressed as a percentage of the nontrypsinized E1 for each sample.
Error bars are the mean   SD. n   3. (D) Exogenous domain III proteins affect the SDS-resistant conformation of the E1 HT. Samples were prepared as
in B. An aliquot of the cell lysate was treated with SDS-sample buffer at 30 C and analyzed by SDS-PAGE and fluorography. For each sample, the SDS-
resistant E1HT band (arrow) was quantitated and expressed as a percentage of the E1HT in the absence of domain III proteins. Representative example
of two experiments. 
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tion by SDS sample buffer at 30
 
 
 
C (Fig. 6 D). Increasing
amounts of domain III proteins lead to the loss of the SDS-
resistant HT conformation, with only 10% of the control HT
observed in the presence of 10 
 
 
 
M His-DIIIS. Interestingly,
bands migrating above and below the position of the E1HT
were clearly observed with His-DIIIS, suggesting the presence
of alternative E1 complexes. A decrease in the SDS-resistant
E1HT was also observed in the presence of increasing amounts
of His-DIII (60% of control HT at 10 
 
 
 
M His-DIII). Together,
these results support a model (Fig. 7) in which exogenous do-
main III binds to an intermediate trimeric conformation of E1
and prevents final hairpin formation and fusion.
 
Discussion
 
In this study, we demonstrated that exogenously added domain
III could inhibit the alphavirus and flavivirus membrane fusion
reactions. Exogenous domain III blocked low pH-induced virus
fusion at the cell surface and within the normal endosomal en-
try pathway and prevented both complete fusion and lipid mix-
ing. Domain III inhibition thus provides proof of principle of a
dominant-negative inhibitor strategy for the class II fusion re-
action and demonstrates the key role of the domain III–core tri-
mer interaction in virus fusion and infection.
Our studies with SFV demonstrate that exogenous do-
main III stably interacted with a trimeric form of E1. Domain
III inhibition thus identifies an important intermediate in the
fusion reaction, defined by the presence of a relatively long-
lived “target” core trimer (Fig. 7 C). The HT structure suggests
that the binding site for exogenous domain III would be located
within the groove formed by two E1 subunits in the central do-
main I/domain II portion of the class II hairpin (Gibbons et al.,
2004b). This model agrees well with our finding that the mono-
mer did not bind domain III because initial oligomerization
would be required to form the critical binding site. The binding
of exogenous domain III to the core trimer was very stable, re-
sisting repeated detergent washes during coimmunoprecipita-
tion. Binding affected the conformation of the HT to varying
extents by preventing the normal folding back of one or more
E1 subunits (Fig. 7). Inhibition showed cross reactivity among
related viruses, in keeping with the presence of conserved resi-
dues in the domain III–core trimer interface. Although our data
do not yet indicate which residues are most critical to the do-
main III interaction, they clearly suggest conservation of key
protein contacts. The SFV E1HT structure indicates that the
AB loop and C
 
 
 
-strand may be important in this interaction
(Gibbons et al., 2004b). Together, the properties of inhibition
indicate that domain III–core trimer binding is an important
step in fusion protein refolding, with the potential to provide
significant driving force in fusion.
Our studies also revealed a strong enhancement of inhibi-
tion by the presence of the fusion protein stem region. We have
tested several stem peptides for their ability to inhibit SFV HT
formation and/or membrane fusion (unpublished data). To date
we have not observed inhibition by the stem region alone, and
thus we hypothesize that domain III acts to orient the stem for
its interaction with the core trimer (but see flavivirus results in
Hrobowski et al., 2005). It may also be that the binding site for
domain III is kinetically favored compared with that of the stem,
which may occur later in the fusion reaction and be relatively
short-lived. Our data are consistent with the exogenous domain
III–core trimer interaction acting as a key first step in inhibition,
with subsequent stem binding along the body of the trimer pro-
viding further stabilization of the inhibitory interaction.
An alternative model for inhibition by domain III is that it
prevents cooperative HT–HT interactions during fusion. Stud-
ies of the membrane insertion of class II fusion protein
ectodomains indicate that insertion is highly cooperative (Gib-
bons et al., 2003; Stiasny et al., 2004). In the case of SFV,
ectodomain insertion produces rings of five to six trimers, re-
Figure 7. Model for SFV E1 conformational changes
during fusion and the action of exogenous domain III.
(A) Prefusion form of E1 on the virus surface, with the E2
protein shown in gray, the E1 domains colored as in Fig.
1 A, and the fusion loop indicated by an orange star.
The virus membrane is shown in brown and the target
membrane is shown in blue. At this stage E1 is mAb
E1a-1negative, trypsin sensitive, and shows no SDS-resis-
tant trimer band (Kielian et al., 2000). (B) Low pH trig-
gers the dissociation of E2/E1 dimer and the initial inter-
action of monomeric E1 with the target membrane. (C)
Proposed membrane-inserted E1 trimer, suggested as a
relatively long-lived intermediate. Subsequent folding
back of domain III and the stem region would drive mem-
brane fusion. (D) Postfusion HT form of E1 with domain III
and the stem region (gray) fully folded back. In this con-
formation, the E1 trimer is mAb E1a-1 positive, trypsin re-
sistant, and SDS resistant (Kielian et al., 2000). (C /C  )
This panel illustrates the interaction of exogenous domain
III (turquoise circle) with the proposed E1 trimer intermediate shown in C. This interaction produces a mixed population of domain III–bound trimers as il-
lustrated by the two states, C  and C  , and the dotted line connecting them. All the states in the mixed population would be blocked from fusing and
would differ in their conformation and biochemical properties. In the C  state, with low concentration and/or low affinity of domain III proteins, some E1
trimers would undergo partial foldback and binding of one exogenous domain III. In the C   state, with high concentration and/or high affinity of domain
III proteins, trimers would bind three exogenous domain III proteins and would be completely blocked in foldback. We predict that the C  state would be
mostly SDS resistant and mAb E1a-1 positive, whereas the C   state would be SDS sensitive and E1a-1 negative. This model is simplified and does not
illustrate the stages of membrane curvature, the potential roles of cooperative trimer interactions, or the initial lipid mixing and pore formation.JCB • VOLUME 171 • NUMBER 1 • 2005 118
flecting the physical associations of adjacent HTs through in-
teractions of their fusion loops and of their domain III regions
(Gibbons et al., 2003, 2004b). These cooperative interactions
produce a volcano-like assembly of E1HTs that may help to in-
duce membrane curvature at the fusion site (Gibbons et al.,
2004b). Although we hypothesize that these intertrimer interac-
tions are important for fusion, we feel that the strongest model
for the action of domain III is that it acts not to prevent interac-
tions between adjacent HTs, but to inhibit the foldback reaction
within one E1 molecule. This agrees well with the resistance of
domain III–E1 binding to octylglucoside, a detergent that we
previously found disrupted HT–HT interactions (Gibbons et
al., 2003, 2004a). It also agrees with the increase in inhibition
and binding that is observed when the stem is present on do-
main III because no role for the stem in HT–HT interactions
was observed in the previous studies. However, domain III
could also be acting by some combination of these two models.
For example, prevention of E1 refolding by binding of exoge-
nous domain III could inhibit the ability of the viral domain III
to interact with an adjacent trimer.
Both the alphavirus and flavivirus fusion reactions are
very rapidly triggered by low pH, with maximal fusion ob-
served within seconds of low pH treatment at 37 C (Kielian et
al., 2000; Heinz and Allison, 2001). Given the speed of the SFV
fusion reaction, it is perhaps surprising that exogenous domain
III can compete with the endogenous domain III for binding to
the core HT. Such an intermolecular interaction of domain III
would seem to be at a disadvantage compared with the intramo-
lecular interaction of the viral domain III. Several factors may
help to explain this paradox. The movement of domain III in the
full-length E1 may be constrained by its attachment to the virus
membrane through the stem/TM domains. Indeed, we found
that binding of exogenous domain III to the E1* ectodomain tri-
mer was not as efficient as binding to the full-length trimer (un-
published data), in keeping with the possibility of a more rapid
foldback of E1* domain III due to the loss of its membrane an-
chor constraint. The structure of the E1 HT also reveals that the
linker region between domain I and III becomes highly ex-
tended during the movement of domain III toward the fusion
loop (Gibbons et al., 2004b). This could provide an additional
constraint to viral domain III movement, favoring the interac-
tion of exogenous domain III with the core trimer.
Previous studies of flavivirus domain III proteins have
focused on their interactions with virus receptors on the cell
surface. Our data identify a novel inhibitory effect of exoge-
nous domain III in the fusion reactions of alphaviruses and fla-
viviruses. Such domain III proteins can serve as useful basic re-
search tools to study alphavirus and flavivirus fusion. Although
unlikely to be directly applicable as antivirals, their inhibitory
activity has important implications for the development of clin-
ically useful inhibitors of the class II fusion reaction. Because
exogenous SFV domain III showed stable binding to a trimeric
E1 target, this interaction could be used to screen for peptides
or small molecules that would block critical domain III–trimer
contacts. Given the cross-inhibition we have observed with
domain III, such screens have the potential to identify broad-
specificity inhibitors of class II fusion proteins.
Materials and methods
Cells and viruses
BHK-21 cells and C6/36 mosquito cells were cultured as previously de-
scribed (Vashishtha et al., 1998). SFV was a well-characterized, plaque-
purified isolate (Vashishtha et al., 1998) and SIN was derived from the in-
fectious clone of Toto 1101 (Rice et al., 1987). VSV expressing GFP
(Boritz et al., 1999) was obtained from J.K. Rose (Yale University, New
Haven, CT), DV2 (strain New Guinea C) from J. Roehrig (Center for Dis-
ease Control, Fort Collins, CO), and DV1 (strain Western Pacific) from R.
Stockert (Albert Einstein College of Medicine, Bronx, NY). SFV, SIN, and
VSV were propagated in BHK-21 cells, and DVs were propagated in C6/
36 cells in DME containing 2% heat-inactivated FCS and 10 mM Hepes,
pH 8.0. 
35S-labeled SFV was prepared as previously described (Vashish-
tha et al., 1998), and 
35S-labeled DV2 was prepared in C6/36 cells (Hil-
gard and Stockert, 2000) and pelleted through a sucrose cushion (Kielian
et al., 1996).
Construction of domain III protein expression plasmids
DNA sequences of SFV E1 domain III (with or without stem region) were
amplified from DNA derived from the infectious SFV clone of Toto1101
(Chatterjee et al., 2002), and the DNA sequences of DV2 E domain III
were obtained by RT-PCR using viral RNA extracted from DV2-infected
C6/36 cells. These sequences were subcloned into the protein expression
plasmid pET-14b (Novogen) to express domain III proteins with an added
NH2-terminal methionine, or the pRSET A plasmid (Invitrogen) to express
NH2-terminal 6  Histidine-tagged domain III proteins with an added NH2-
terminal 36 amino acids, and confirmed by DNA sequencing.
Protein expression, refolding, and purification
Domain III proteins were expressed and refolded essentially as described
for other Ig-like domain proteins (X. Zhang et al., 2002). In brief, proteins
were expressed in E. coli strain BL21(DE3), solubilized from inclusion bod-
ies in buffer containing 6 M guanidine-HCl, refolded by the fast dilution
method, and purified by fast protein liquid chromatography on a Super-
dex G-75 gel filtration column (GE Healthcare). The concentration of
purified domain III proteins was determined by absorption at 205 nm
(Scopes, 1974).
Protein analysis
The mass of domain III proteins was measured by ESI mass spectrometry
using a Finnigan LCQ ion trap mass spectrometer (Thermo Electron Corpo-
ration). Analysis by SDS-PAGE was performed using a standard Tris–gly-
cine system and 11% acrylamide gels, except in Fig. 1 C, where a Tris–tri-
cine buffer system and 16.5% acrylamide gels were used (Gibbons and
Kielian, 2002). 
35S-labeled proteins were quantitated by PhosphorImager
analysis with Image Quant version 1.2 software (Molecular Dynamics).
FIA
Fusion of viruses with the plasma membrane of BHK cells was assayed us-
ing a variation of a previously described SFV FIA (Vashishtha et al.,
1998). BHK cells grown on 12-mm coverslips in 24-well plates were
washed twice with ice cold binding medium (RPMI without bicarbonate,
plus 0.2% BSA, 10 mM Hepes, and 20 mM NH4Cl) at the indicated pH.
Cells were incubated on ice for 90 to 120 min with gentle shaking with
SFV and SIN in binding medium plus 20 mM MES, pH 6.8, or with DVs
in binding medium, pH 7.9. Cells were washed twice with binding me-
dium to remove unbound virus and pulsed for 1 min at 37 C in 200  l
pH medium (RPMI/BSA/Hepes plus 30 mM MES for pH 7.4 or RPMI/
BSA/Hepes plus 30 mM sodium succinate for pH 6.0 or lower). SFV- and
SIN-infected cells were incubated at 28 C overnight in BHK growth me-
dium plus 20 mM NH4Cl; DV-infected cells were incubated in MEM plus
2% FCS and 50 mM NH4Cl for 3 h at 37 C, and then at 37 C for 2 d in
the presence of 20 mM NH4Cl. Domain III proteins were added at spe-
cific steps as indicated. The threshold for DV fusion (approximately pH
7.0) was higher than that of SFV, with maximal DV fusion observed at ap-
proximately pH 6.2 and below, resulting in infection by  30% of the
bound infectious DV.
Immunofluorescence microscopy
VSV-infected cells were fixed in 3% formaldehyde at RT for 20 min and
GFP-expressing cells were quantitated by fluorescence microscopy. Cells in-
fected by all other viruses were fixed in ice-cold methanol for 10 min. SFV-
and SIN-infected cells were stained with rabbit polyclonal antisera against
SFV or SIN envelope proteins and fluorescein-conjugated secondary anti-
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with a mouse polyclonal hyperimmune ascitic fluid against DV2 (obtained
from R.B. Tesh, University of Texas Medical Branch, Galveston, TX), fol-
lowed by an Alexafluor 488–conjugated secondary antibody (Molecular
Probes). For each sample, duplicate coverslips were evaluated at an infec-
tion level of  200 positive cells/coverslip in the absence of inhibitor.
Assays of the SFV E1 HT
To assess the conformational change of SFV E1 protein during fusion in
the presence of domain III proteins, purified 
35S-labeled SFV was bound to
BHK cells on ice and pulsed at low pH, as in the FIA. The cells were
washed to remove exogenous domain III and solubilized in lysis buffer (20
mM Tris, pH 7.4, 100 mM NaCl, 1.5% octylglucoside, 1 mM EDTA, plus
1  g/ml pepstatin, 50  g/ml leupeptin, 0.1% BSA, 100  g/ml aproti-
nin, and 1 mM PMSF). To quantitate the SDS-resistant E1 HT, an aliquot of
each lysate was added to SDS sample buffer and heated to 30 C for 3
min before SDS-PAGE. Another aliquot of cell lysate was subjected to im-
munoprecipitation (Kielian et al., 1996) using the indicated antibodies
and zysorbin as immunosorbant, and analyzed by SDS-PAGE.
To test trypsin resistance, the zysorbin with retrieved immunoprecip-
itate was pelleted, resuspended in PBS containing 1% Triton X-100, and
digested with 125  g/ml trypsin at 37 C for 1 h. The digestion was
stopped by adding 5 mM PMSF. The zysorbin was eluted by treatment
with 2% SDS and three cycles of heating to 95 C for 3 min. It was pelleted
and the supernatants were concentrated by acid precipitation and ana-
lyzed by SDS-PAGE.
Pyrene-labeled SFV fusion with cells
Pyrene-labeled SFV was prepared by propagation of virus in BHK cells
metabolically labeled with C16-pyrene (Chatterjee et al., 2002) and tested
using a protocol similar to the FIA. Virus was bound on ice for 120 min to
BHK cells on 35-mm plates at a multiplicity of  2,000 pfu/cell. Virus fu-
sion was induced at 37 C for 1 min in pH 7.4 or 5.5 medium. Cells were
put back on ice and washed once with binding medium at pH 6.8 and
once with H-H solution (HBSS containing 10 mM Hepes, pH 7.4, and 20
mM NH4Cl). The cells were scraped in H-H solution, transferred to a
quartz cuvette, and the emission spectrum determined using an AB-2 fluo-
rometer (Thermo Electron Corporation) at 37 C with an excitation wave-
length of 343 nm (Chatterjee et al., 2002). The fluorescence emission
from 360 to 560 nm was recorded as the average of two serial scans,
and the background fluorescence from cells alone was subtracted from
each sample. The excimer and monomer peaks were determined at emis-
sion wavelengths of 475 and 397 nm, respectively.
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